




James Barlow
CEO & President
ImmunoGenesis

Jim Barlow became the CEO of ImmunoGenesis in April 2020. Before joining ImmunoGenesis, Mr. Barlow was Vice President of Operations and Business Development for Geneos Therapeutics. Mr. Barlow played an integral role in the formation of Geneos, a personalized neoantigen-targeting cancer vaccine company spun off from Inovio Pharmaceuticals. One of 2 initial employees, Mr. Barlow helped to build the management team and establish all key operational aspects of the company. He also led the tumor prioritization efforts, resulting in the design and initiation of the company's first clinical trial less than 9 months after obtaining Series A financing.

Before joining Geneos, Mr. Barlow drove the development of Inovio's Immuno-oncology (IO) product strategy. In this effort, he led a cross-functional team across Commercial, Clinical, Product Development, R&D, and Business Development to establish a set of key strategic principles. Mr. Barlow led the product prioritization efforts based on these principles, established the IO Advisory Panel, and coordinated key opinion leader and pharma partner interactions to position the company to embark on major clinical programs across 4 tumor types of interest. These programs evaluated combination regimens of Inovio's cancer immunotherapies with PD-L1 inhibitors from 3 different pharma partners. Mr. Barlow established 2 of these 3 partnerships, as well as a clinical partnership with the Parker Institute for Cancer Immunotherapy.

Prior to Inovio, Mr. Barlow was at Bristol-Myers Squibb (BMS), where he was the Payer Marketing Lead for Yervoy, the pioneering cancer immunotherapy whose approval set off the current wave of immunotherapy development in oncology. Given the first-in-class nature of the product and the premium price associated with it, Mr. Barlow created a number of innovative programs to optimize market access. While at BMS, Mr. Barlow also worked on the overall IO franchise commercial strategy, including the development of communication planning for the groundbreaking immunotherapy Opdivo. Before his tenure at BMS, Mr. Barlow spent 8 years at Merck working in commercial leadership roles with increasing responsibility for the oncology franchise.

Mr. Barlow received an MBA (strategy and marketing) with honors from the Tepper School of Business at Carnegie Mellon University. He was awarded the Dean's Scholarship from Tepper. Mr. Barlow received a BA in Math and Economics from Colgate University, where he was awarded the Alumni Memorial Scholarship and graduated summa cum laude.



Meg Boulware, J.D.
Partner
Boulware & Valoir PLLC

Practice Areas
Intellectual Property

Practice Focus

Patent practice with emphasis on chemistry and biotechnology; contested trademark matters and global portfolio advice and intellectual property litigation.

Practice Description

In 2010, Ms. Boulware started a woman-owned boutique firm building on her years of experience in international and domestic IP work. She tried the first validity and infringement arbitration of a U.S. patent, which case was tried before the International Chamber of Commerce. She has

represented clients in trademark infringement cases including over 100 cases before federal courts and the U.S. Patent and Trademark Office. In addition to litigation experience, Ms. Boulware has prosecuted patents in chemical, mechanical and biotech areas. She procured pioneer patents on cattle cloning in the U.S. Ms. Boulware supervises international trademark portfolios and advises on international market strategies for clients including Fortune 500 companies. Meg was the first woman president of the American Intellectual Property Law Association and is active in national IP associations.

Awards and Honors

In 2012 Ms. Boulware received the first ever Americas Women in Business Law Award for Best in Patent (www.expertguides.com). Since 2005, Ms. Boulware has been recognized in Chambers USA – Leaders in their Field. She also has been included in The Best Lawyers in America for Intellectual Property in IP Law & Business since 2006, and has been selected to The International Who's Who of Business Lawyers and Best Lawyers in America for the past 15 years along with numerous other recognitions both international and U.S. In addition, she is active in community activities and is a Trustee of the Houston Grand Opera and served on the Board of the Clemson University Foundation.

Professional Affiliations

BioHouston, Inc., Board Member
American Intellectual Property Law Association, past President
Patent Public Advisory Committee, U.S. Patent and Trademark Office,
appointed by the Secretary of Commerce as inaugural Chair 1999-2002
State Bar of Texas, Intellectual Property Section, past Chair
Houston Intellectual Property Law Association, past President
Advisory Board of the University of Houston Law Center Intellectual
Property Law Program, Founding Chair
Texas Bar Foundation, Life Fellow
Houston Bar Foundation, Life Fellow
National Coordinator of the Bicentennial Celebration of the Patent and
Copyright Laws 1990 in Washington, D.C. while serving as a Board member
of the Foundation for a Creative America

Bar Admittance

Texas
United States Patent and Trademark Office

Education

B.S., University of Georgia
M.S., Clemson University
J.D., University of Houston Law Center



Fraser Brown, Ph.D., J.D.
Partner
Cooley

Dr. Fraser Brown is a partner in the patent counseling and prosecution practice. His practice focuses on biotechnology issues, with particular emphasis on drafting and prosecuting patent applications, and preparing invalidity, freedom to operate and patentability opinions. Fraser has also negotiated agreements to further clients' collaborative research and development strategies. He has counseled clients on a range of technical areas including vaccines, fluorescent proteins, drug design and screening, and cancer therapies.



Jeff Buel
Director, Texas Government Affairs
Johnson and Johnson

Jeff Buel is Director of State Government Affairs for Johnson & Johnson. His focus includes management of interactive contacts with executive, legislative, administrative, and regulatory branches related to the State Government's, Public Health and Medicaid.

During 25 years in the HealthCare Industry, Jeff has held numerous positions of increasing responsibility in sales management, marketing and government affairs. He has worked as a District Manager, Product Manager, Marketing Director, Regional Business Director, National Account Director and Director of Government Accounts.

Prior to J&J, Jeff was a Regional Director for Astra Pharmaceuticals for 13 years and led Astra's US expansion by recruiting, training and leading sales force of 12 District Managers and 100 Sales Professionals. Emphasize long term growth and success with empowerment, job effectiveness and fulfillment of individual potential being the goal. Developed and implemented marketing plans and strategies for increased market share and sales volume. Strong corporate leadership role.

Jeff served as a Commissioned officer in the US Army and Army National Guard for 19 years reaching the rank of Captain.



Brad Burke
Texas Life Science Forum Co-Host
Managing Director
Rice Alliance for Technology and Entrepreneurship

Brad Burke is the Managing Director of the Rice Alliance and has led the Rice Alliance since 2001. During that time, Rice's graduate entrepreneurship program has achieved the #1 ranking in the U.S. (having been previously unranked). The Rice Alliance's Rice Business Plan Competition has become the world's largest and richest student startup competition in the world. Previously, Brad founded and managed the Houston office of Viant Corporation, a premier internet consulting firm, that went public via IPO in 1999, before being acquired in 2002. Prior to Viant, Brad was a Principal with CSC Index, the former management consulting division of Computer Sciences Corporation (CSC). Before CSC, Brad held executive management positions with Exxon. He received his M.B.A. from Northwestern University's Kellogg Graduate School of Management as an Austin Scholar and his BS from Vanderbilt University.



Rima Chakrabarti, M.D.
Partner
KdT Ventures


Amateur mom, Doctor, Provider, Baby food chef, Ukelele novice

As a physician-scientist with a background in clinical neurology and early stage technology commercialization, Rima's experience pushing nascent technologies to market drives forward KdT's mission to support founders who can engineer the world's molecular layer.



Shahila Christie, Ph.D.
VP, Growth Strategy and Operations
Portal Innovations

Shahila Christie is the Vice-President of Growth Strategy and Operations at Portal Innovations. Over her 20 yr career Shahila spent the initial part as an academic researcher and then moved into the entrepreneurial space when she founded a startup as a university spinout based on her research project. She enjoys driving scientific strategy from a business perspective and has held various roles including consulting for startups and leading the clinical efforts for a medical device company in the oncology diagnostic space. In her current role Shahila ties these varied experiences together to help Portal Innovations grow and expand. Her role focuses on understanding life science ecosystem in cities beyond Chicago and building and implementing the Portal playbook to launch the platform in cities of interest nationwide.



Joseph M. Conrad III, Ph.D., J.D.
Senior Technology Analysis and Marketing Specialist
National Cancer Institute

Dr. Joseph M. Conrad III received his Ph.D. in biochemistry from American University and his J.D. from George Washington University Washington College of Law. He's also a former U.S. Patent Office chemical/pharmaceutical patent Examiner. He worked for two DC patent law firms over a five-year period doing pharmaceutical and biotech patent preparation and prosecution; and then transitioned to the NIH's National Institute of Allergy and Infectious Diseases' (NIAID's) Office of Technology Development (OTD), where he was responsible for overseeing/co-management of NIAID's patent portfolio and educating scientists on patent related matters. He then joined the National Cancer Institute's (NCI's) Technology Transfer Center (TTC), where he was responsible for negotiating technology transfer agreements and overseeing invention activities for the National Institute of Child Health and Human Development (NICHD). In 2014, he joined TTC's newly formed Technology Analysis and Marketing Unit (TAMU) and is now a Senior Technology Analysis & Marketing Specialist. In this position, Dr. Conrad is responsible for developing and improving TTC technology marketing activities; increasing awareness of licensing and partnering opportunities with the NCI (and other NIH Institutes); increasing technology visibility to the private sector and improving relationships with private sector stakeholders.



Sarah Daoudi
Field Application Scientist, Cell & Gene Therapy
Thermo Fisher Scientific

Sarah Daoudi is a Field Application Scientist that provides solutions and consultation for Thermo Fisher Scientific's cell and gene therapy workflows and Gibco Cell Therapy Systems (CTS) brand of products. Sarah has expertise in CAR-T workflows, manufacturing, viral vector production (lentivirus and adeno-associated viruses), and drug development. Formerly a Scientist II at Thermo Fisher Scientific, she helped launch the CTS Rotea System by producing application data, writing and developing new protocols, as well as extensive troubleshooting and customer support. In her previous role as Process Development Research Associate at City of Hope (Duarte, California), Sarah oversaw and worked on improving, troubleshooting, and development of Phase I CAR-T cell therapeutic drugs and workflows for over ten different IRBs. Sarah received her master's degree in Cell and Molecular Biology from California State University, Fullerton (California).



Susan Davenport
Senior Vice President and Chief Economic Development Officer
Greater Houston Partnership

Susan Davenport serves as Senior Vice President and Chief Economic Development Officer at the Greater Houston Partnership. The Partnership is an approximately 900-member business partnership encompassing a 12-county greater Houston region. In this role, Susan leads the organization's domestic and international economic development efforts and provides assistance to companies considering expanding, relocating or investing in the greater Houston region.

Prior to her work in Houston, Susan served as the President/CEO of the Gainesville Area Chamber of Commerce, a five-star accredited Chamber with approximately 1,300 member companies and organizations. Prior to her role as President/CEO she served for two years as the Chamber's Vice President of Economic Development. From 2013 through 2018, the Gainesville Chamber announced the creation of more than 1,100 new jobs and more than \$400 million in new capital investment.

Susan came to Gainesville in 2013 after spending 13 years with the Austin Chamber of Commerce, most recently as Senior Vice President of Global Tech Strategies. While there she served as a key team member for the Opportunity Austin strategy which created over 174,000 new jobs and enhanced regional payrolls by \$8.7 billion over an 8-year period from 2004-2012. During her tenure in Austin she developed and executed Austin's regional business retention and expansion program, Portfolio Austin, where over 4,800 regional retention visits were undertaken with 520 regional expansions tracked. She also developed and managed the Central Texas Regional Center for Innovation and Commercialization, which resulted in assisting 34 companies accessing \$60 million in funding with an additional \$30 million for local research and university projects. Susan also developed the Greater Austin Technology Partnership and Austin TechLive, which engaged over 100 regional technology executives in various economic development activities and supported entrepreneurship through a downtown co-working technology hub partner.

Susan received a Master of Public Affairs from The University of Texas at Austin and earned a Bachelor of Science degree in Nursing from The University of Texas Medical Branch. She is also a graduate of the Economic Development Institute at the University of Oklahoma and is an active member of International Economic Development Council.



Tracey Davies, J.D., MPH
Chief Strategic Initiatives Officer, Chief Intellectual Property Officer
Cancer Prevention & Research Institute of Texas (CPRIT)

Tracey Davies has more than 20 years of experience advising life science companies at all stages of development and research institutions across a broad range of business and legal issues. She is also a licensed patent attorney.

Prior to joining CPRIT, she was a partner with Gibson Dunn & Crutcher L.L.P., and co-chaired the firm's Life Sciences practice as well as serving as a member of the firm's Intellectual Property and Litigation practice groups. Previously, Davies was a partner and member of the Executive Management Committee at Vinson & Elkins, L.L.P., where she led the firm's Intellectual Property, Technology and Life Science practices.

Davies received her J.D. and master's degree in Public Health from the University of Minnesota.



Kristin Doyle, J.D.
Deputy Executive Officer and General Counsel
Cancer Prevention & Research Institute of Texas (CPRIT)

Ms. Doyle joined CPRIT in July of 2009. She now is responsible for overseeing the legal issues that arise as part of CPRIT's operations, including grant award contract negotiations, intellectual property and revenue sharing agreements, conflicts of interest and confidentiality, and regulatory/compliance issues. Prior to joining CPRIT, Ms. Doyle was a partner at an Austin-based law firm and served as Vice President of the Board of Directors for the Central Texas Chapter for the Leukemia and Lymphoma Society.

Ms. Doyle has spent the majority of her legal career practicing administrative law, with an emphasis in the field of energy and regulatory law. She received her undergraduate degree in Public Policy, magna cum laude, from Indiana University and her doctorate of Jurisprudence from The University of Texas at Austin School of Law. In 2012, Ms. Doyle received her Masters of Science in Technology Commercialization from the McCombs School of Business at The University of Texas at Austin. She is a frequent speaker on administrative law and legislative policy issues.



John Forrest, J.D.
Associate
Cooley

John represents pharmaceutical, biotechnology and other life sciences companies in a wide range of IP-related and commercial transactions, including licensing agreements, research collaborations and strategic partnering agreements.



Rebekah Gandy, AIA, CDT, LEED AP
Architect, Senior Associate
Gensler

Rebekah brings 11 years of experience in multiple market sectors, including Higher Education and Science + Technology. Her collegiate career began with a focus In Electrical Engineering, making the transition to lab design a natural one. This diverse yet focused experience has made Rebekah an expert in the intricacies and challenges that science +technology projects can involve. Her passion for highly technical and innovative design fuels her drive for creating inspirational environments that catalyze the user's creative potential.

As an avid knowledge explorer, Rebekah actively incorporates new industry ideas and possibilities into her project for her clients. She is committed to her projects and clients from early schematic design to post occupancy. Rebekah is a firm believer in a collaborative design process and takes purposeful actions to help facilitate the involvement of all team members. Through this collaborative design process, she has been successful in delivering technically complicated projects in an efficient manner.




Billy Grandy
Director
Softeq Venture Studio

I help build teams and brands. From Action Sports to Consumer Electronics and few things in between. Helpings several companies go from startup to national & international distribution. Several of the companies have been listed on the INC 500/5000. Personally managed and opened key account relationships from Amazon, Quidsi, Walmart, Target, Toys R Us, Nordstrom, Apple, Bloomingdales, At&t, etc.



Natalie Harms
Editor
InnovationMap

I am the inaugural editor at InnovationMap. I am a journalist based in Houston, Texas. I cover tech and startups in Houston and prefer email to DMs — natalie@innovationmap.com. I also co-created and run a Houston lifestyle blog, It's Not Hou It's Me. I post about food, exercise, life, travel, and more.




Sarah Hein, Ph.D.
CEO
March Biosciences

Sarah is the founding CEO of March Biosciences, a clinical-stage cell-therapy company targeting challenging hematological malignancies. Prior to cofounding March Bio, she was the founding Entrepreneur in Residence for the Texas Medical Center Innovation Accelerator for Cancer Therapeutics (TMCi ACT). Formerly, she was a cofounder and the Vice President of Operations at Courier Therapeutics, a cancer immunotherapy startup acquired by Valo Health. She was also Director of Research at Resonant Therapeutics, an antibody therapeutics platform technology company. She began at Mercury Fund as a Venture Fellow directly after graduating with her Ph.D. in Molecular Biology from Baylor College of Medicine.




James Hury
Deputy Director & Chief Innovation Officer
Translational Research Institute for Space Health (TRISH)

James Hury is the Deputy Director and Chief Innovation Officer for the Translational Research Institute for Space Health. In this role, Mr. Hury executes TRISH's vision by finding and funding the most impactful emerging health and human performance technologies to aid NASA's deep space exploration, which includes the Artemis missions and the Mars missions.




Annie Kadota
Vice President, Southwest Life Science & Healthcare
Silicon Valley Bank

Annie Kadota is a VP in Silicon Valley Bank (SVB)'s Life Science and Healthcare Banking Solutions group, Southwest Region, where her specialty in venture debt supports the team's deep expertise in providing financial solutions to high-growth public and private life science companies. Annie joined SVB in 2014 based in the Bay Area and returned to her hometown of San Diego in 2015 to join the Life Science Practice. Annie also serves as a committee chair for the Southern California chapter of Women in Bio, which promotes careers, leadership and entrepreneurship in the second-largest biotech hub in the United States. Annie graduated with a bachelor's degree in sports management from Rice University, where she'd earned numerous academic and athletic awards as a four-year letter winner on the varsity soccer team. Outside of the office, Annie enjoys playing soccer, skiing in Whistler, and practicing piano/guitar.



James Lancaster
CEO
Solenic Medical

James Y. Lancaster, Chief Executive Officer, is a seasoned entrepreneur and business development executive with 30 years of experience across multiple industries. He was most recently the Founder and Managing Director of the Innovate Family of Companies with client technologies including a variety of software, innovative materials, internet-of-things, robotics, autonomous vehicles, drone technologies, medical device, biological control, and waste recycling technologies. Prior to becoming an entrepreneur, he worked for Deloitte Consulting in Dallas with Fortune 500 and held other executive positions in business software and services, medical technologies, and IT solutions.




Michael Lewis
Chief Innovation Officer
Nanoracks

Mike Lewis is currently the Chief Innovation Officer at Nanoracks, LLC, where he is responsible for overseeing the technical, scientific, and engineering direction for the company. He has developed, built, and flown experiment platforms to the ISS, and has helped deliver over 1,300 experiments to space.



Adam Lipman
Co-Founder & Managing Partner
Ecliptic Capital

Adam Lipman is the Managing Partner at Ecliptic Capital and Optimal Symmetry. He has a diverse background that spans multiple industries. He spent over a decade with one of the world's largest biotech companies as both a technologist and a leader of a global team. Most recently he spent two and a half years as Chief Operating Officer for one of the top mobile software development studios in the world. While there he led this game-changing software development company to new heights and helped shape the digital presence of many of the world's leading brands. Adam holds a BS in Molecular Biology and an MBA from UC Davis.



Danielle Lobsinger Bush
Director of Policy
Texas Healthcare and Bioscience Institute (THBI)

Danielle Lobsinger Bush is the director of policy for the Texas Healthcare and Bioscience Institute—a trade association representing the life science industry in Texas. As director of policy, she plays a key role advocating on issues important to the life sciences industry in Texas at both the state and federal level. She has nearly 10 years of legislative engagement and public policy advocacy experience. In her previous roles as assistant director of policy and as a government relations specialist at the Texas Health and Human Services Commission, she received in-depth exposure to the leadership decision-making in important government health-related programs, including the Texas Medicaid Program, and she also had firsthand experience navigating the relationships between the agency and the Texas Legislature. Prior to that, Bush worked both for a statewide trade association, engaged in front-line advocacy efforts, and in the Texas Capitol, learning the legislative process firsthand as a district director and legislative aide for a State Representative. She holds a bachelor's degree from the University of Missouri.




Tom Luby, Ph.D.
Director, Innovation
TMC Innovation

Tom Luby Ph.D. is the Director of Texas Medical Center (TMC) Innovation. In this role, he oversees all of the innovation efforts of TMC focused on research, education, and commercialization of novel healthcare solutions. Prior to this, he was the head of JLABS @ TMC in Houston, Texas. In that role, he catalyzes and supports the translation of science and technology into valuable solutions for patients and consumers across the pharmaceutical, medical device and consumer healthcare sectors.

Tom started at Johnson & Johnson Innovation as a New Ventures Lead at the Johnson & Johnson Innovation Center in Boston. In that role, he was instrumental in fostering many deals for the Boston office, which included the expansion of JLABS to JLABS @ Toronto. Prior to J&J, Tom spent 14 years in various R&D and business development positions, most recently as Sr. Director, Research Ventures at Shire. Nine of those years were spent working in R&D and operational roles across three start-up biotech companies in the Boston area.

Tom received a Bachelor of Science in Biology from State University of New York, and a Ph.D. in Immunology from the Sackler School of Biomedical Sciences at Tufts University.




Michael Mencher
Special Counsel
Cooley

Michael represents public and late-stage private life sciences and technology companies in a broad range of corporate matters, with an emphasis on corporate governance and SEC reporting advice. He counsels public companies and their boards on securities regulation and governance issues, including Exchange Act reporting, annual meetings, shareholder activism, insider trading, and board structure and composition matters. Michael also advises companies on environmental, social, and governance (ESG) matters, including sustainability reporting, board oversight and disclosure controls, and shareholder and stakeholder engagement. Michael regularly assists IPO and deSPAC companies on public company readiness matters, and he works closely with newly public companies on their initial SEC reporting and establishing key governance and SEC compliance processes. In addition, he has extensive experience representing public companies in various securities offerings, such as IPOs, registered debt and equity offerings, private investment in public equity (PIPE) deals, and sustainable finance transactions.



Junaid Mian, R.Ph.
General Partner
SpaceFund

Junaid Mian is a pharmacist, entrepreneur, and investor. He is currently a General Partner at SpaceFund, a Houston-based VC firm, putting his skills to work in exploring how space can benefit human health span and lifespan.



Isaac Middleton, J.D.
Chief Operating Officer
Texas Medical Center

Isaac Middleton is the Chief Operating Officer of the Texas Medical Center. He is responsible for day-to-day operations as well as developing and driving critical initiatives in support of Texas Medical Center's strategic vision. Isaac joined Texas Medical Center in 2020.

Isaac previously served as a management consultant where he focused on strategy, operations, and capital excellence across the Logistics, Transportation, Real Estate, and High Tech industries. Isaac led global teams working on top-priority strategic initiatives for his clients throughout the United States, Europe, and Asia.

Prior to consulting, Isaac served as a commissioned officer in the United States Marine Corps, during this time he deployed to Iraq as part of a Light Armored Reconnaissance battalion.

Isaac holds a Bachelor of Arts in Economics from Marquette University, and a Juris Doctor from Stanford Law School.



Joanna Nathan, MBA
CEO
Prana Thoracic

"I am an investor turned entrepreneur on a mission to improve outcomes for lung cancer patients as the CEO of Prana Thoracic. Our technology is the first minimally invasive medical device to enable early diagnosis and intervention in lung cancer.

At the start of my career, I received the gift of entrepreneurship, an unexpected pivot that changed my path from research to innovation. My roles as Research Engineer at Texas Heart Institute and Director of Product Development at Saranas taught me what it takes to bring innovative technologies from idea to reality. My work at Mercury Fund, followed by my role as New Ventures Manager at Johnson & Johnson MedTech Center for Device Innovation expanded my perspective on innovation to include the investor mindset and ultimately led me to step back into an entrepreneurial role with Prana Thoracic.

I am invested in growing and supporting Houston's life science community. I've mentored countless founders, and continue to advocate for students and aspiring entrepreneurs, as co-founder of Enventure and as President of the Board for Rice University Engineering Alumni.

I'm looking to connect with investors and clinical investigators working to improve outcomes for lung cancer patients."



Jan Odegard, Ph.D.
Executive Director
The Ion

Dr. Odegard is the Executive Director at The Ion. The Ion is a nucleus for innovation in Houston, fostering a community and culture where entrepreneurs and corporations come together to solve some of the world's greatest problems. Prior to joining The Ion, Odegard served as the Executive Director of the Ken Kennedy Institute at Rice University (2002-2019), where he focused on building strategic partnerships to serve as catalysts for research, education, and external engagements in data and computing. Odegard has over 25 years of experience supporting and enabling research and life-long learning engagements in computing, data science, and information technology. During his tenure at Rice, Odegard also served as the Associate VP for Research Computing (2015-2019). While at Rice, Odegard worked with colleagues in the industry to launch the Oil & Gas High-Performance Computing Conference series in spring 2008 and in 2017 launched the Ken Kennedy Institute Data Science Conference series.

Odegard was an associate professor in the Department of Electrical and Computer Engineering at the University of Stavanger, Norway, (1999-2001), and served as department chair (2000-2001). From 1996 to 1997, he was the founding executive director of the Computational Mathematics Laboratory and research associate in Electrical and Computer Engineering at Rice. From 1997 to 1999, he served as the founding executive director of the Rice Center for Multimedia Communication. Odegard received the Michael Pearlman Memorial Service Award from Rice University in 2009 and was elected Senior Member of IEEE in 2002, is a ACM member, and elected member of the academic honor societies Sigma Xi, Tau Beta Pi, Eta Kappa Nu, and Phi Kappa Phi.

Odegard received his Ph.D. in electrical and computer engineering from Rice University in 1996, earned a Bachelor of Science degree (1987) and a Master of Science degree (1990), both from Texas A&M University in electrical engineering, and holds an associate degree (1986) in electrical engineering from Telemark College of Engineering, Porsgrunn, Norway.



Jennifer Oliverio
Senior Vice President
Transwestern

Jennifer Oliverio serves as Senior Vice President and oversees the design and construction of developments from master planning through occupancy. She manages projects both small and large, with an emphasis on life science and healthcare projects.

With her experience managing over 2 million square feet of life science and healthcare projects, she understands the complexities of these developments, including building infrastructure requirements, vivariums, hazardous materials storage strategies, life safety issues, equipment planning, clean room planning and installation, biology labs, chemistry labs, academic labs, and biotech manufacturing. She aids teams in all phases of development, including master planning, core and shell, and tenant fit out, including the 37-acre TMC3 life science development in Houston, Texas.

Prior to joining Transwestern, she led the Houston office of DPR Construction where she was responsible for new business generation as well as execution of projects in the Greater Houston area. Prior to that, she worked for Linbeck Construction for over a decade, where she managed hospital, higher education, commercial, and laboratory projects across Houston.

In addition to life science and healthcare projects, she has overseen a broad range of teams and project types, including healthcare, commercial office, mixed use, hospitality, advanced technology, and higher education. During her career, she has worked with many Texas healthcare institutions, including: M.D. Anderson, Texas Children's Hospital, University of Texas Health Science Center, University of Texas Medical Branch Galveston, University of Houston, Memorial Hermann Health System, CHI, Houston Methodist, Texas Medical Center, and Rice University. Jennifer holds a bachelor's degree in Construction Science from Texas A&M University.



Frank Perabo, M.D., Ph.D.
CEO
Tachyon Therapeutics

Dr. Perabo is a Life Science Executive and Entrepreneur with over 20 years' R&D experience in Pharma and Biotech. He has founded and co-founded several Biotech companies (Barricade Therapeutics, MAIA Biotechnology). He has also served as Chief Medical Officer and Executive Vice President of Development of ESSA Pharmaceuticals and Executive Director at Astellas Pharma where he was instrumental in the development and worldwide approval of XTANDI® (Enzalutamide). Dr. Perabo has a proven track record in leading successful early and late-phase clinical development programs with extensive regulatory interactions globally. Dr. Perabo obtained his medical training at the Universities of Munich, Freiburg and Bonn after graduating magna cum laude from medical school at the University of Munich, with a Ph.D. in Cancer Biology.



Rachel Rath, MPH
Interim Head, JLABS @ TMC;
Director, BARDA Alliance

Rachel is the Director of the BARDA Alliance for Johnson & Johnson Innovation, based at JLABS Washington, DC. In this role, she manages the collaboration between JLABS and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, which is focused on emerging technologies and the advancement of medical countermeasures aimed at securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID).

Before joining JLABS, Rachel was the Chief of Staff for the National Evaluation System for health Technology Coordinating (NESTcc)—an initiative of the Medical Device Innovation Consortium (MDIC). Rachel helped lead the development of NESTcc and managed strategy and operations, including overseeing governance, communications, sustainability planning, and stakeholder engagement. Prior to her work at M.D.IC, Rachel was based at the Patient-Centered Outcomes Research Institute (PCORI), helping to launch the Patient-Centered Clinical Research Network (PCORnet), a national effort to engage patients and leverage electronic health data to improve the speed and efficiency of clinical research in the United States.

She earned an MBA from Georgetown University and an MPH in Global Health Policy from George Washington University.



John (JR) Reale
Venture Lead, TMC Venture Fund;
Managing Director, Integr8d Capital

John S. Reale, Jr. (JR) serves as Executive in Residence (EIR) at TMC Innovation. As EIR, he is an in-house resource for companies throughout the community. In addition, he advises the Healthcare Accelerator on strategy to advance how the TMC delivers value to its Member Institutions and entrepreneurs. JR also leads the TMC Venture Fund, a \$25 M fund that invests in early-stage companies changing the face of healthcare connecting through the Texas Medical Center.

JR is an experienced early-stage technology company investor, entrepreneur and executive. JR founded Integr8d Capital, an early-stage venture capital firm launched in 2017. Integr8d Capital partners with founders launching their ventures in-and-through the City of Houston to build transformative companies.

Previously, he co-founded Station Houston, Inc. (Station), Houston's hub for tech innovation and entrepreneurship, where he served as its CEO from inception through August 2018. In April 2018, Station announced its partnership with the City of Houston, Rice University and the Texas Medical Center to develop and launch the Houston Innovation District in midtown Houston. Prior to Station, he was an Operating Partner with Fraser McCombs Capital (FMC), an early-stage venture capital firm based in Boulder and San Antonio. Through FMC, JR served in various leadership roles with their portfolio companies. JR founded Arete which advises early-stage companies on their launch and growth operations. JR started his career in financial services at Morgan Stanley and JP Morgan, as well as Founding Member of Avalon Advisors, a wealth management and advisory firm based in Houston.

Civically, JR serves a variety of organizations focused on education and entrepreneurship. Most notably, JR Chaired Mayor Sylvester Turner's Innovation and Technology Task Force to further the City of

Houston's strategy and plan to spark the long-term growth of Houston's innovation and technology entrepreneurship economy. Additionally, he served on the Greater Houston Partnership's Innovation Advisory Board. These task forces helped lead to the formation of Houston Exponential (HX), an organization charged with sustainably promoting Houston's entrepreneurship and innovation economy. JR currently serves on the Board of HX, where amongst its initiatives, helped launch the HX Venture Fund, a fund of fund venture model to attract more venture capital to the region.

JR serves on the Advisory Board for the Rice Alliance for Technology and Entrepreneurship; the Investment Committee for the Cougar Venture Fund at the University of Houston; as Entrepreneur in Residence for the Liu Idea Lab for Innovation and Entrepreneurship (LILIE) at Rice University; was the past-President of The Indus Entrepreneurs (TiE) Houston chapter; and mentor at numerous start-up acceleration programs. JR is a member of the Startup Champions Network, a national organization of startup ecosystem leaders. Finally, JR co-founded the Mentoring Initiative at Cristo Rey Jesuit Preparatory High School in Houston (Viva Cristo Rey!).

JR received his BS in Finance and Investments from Babson College in Massachusetts. JR and his wife, Kim, are the proud parents of the first Houston-born member of their family, their daughter, Juliana!



Emily Reiser, Ph.D.
Associate Director
TMC Innovation

Dr. Emily Reiser is the Associate Director of TMC Innovation's Accelerator for health tech and Biodesign programs. Emily served previously as the Innovation Community Engagement Senior Manager and draws on her extensive experience managing the TMC Innovation network ensuring all stakeholders have the opportunity to connect to the resources they need to be successful.

For several years she has supported and influenced the Houston life science innovation community through her work at the Texas Medical Center, and previously via her leadership role with Enventure, a grassroots, non-profit organization supporting entrepreneurship training and life science company formation. Emily also worked directly with TMCi Accelerator company, Noleus Technologies, directing business development.

Emily earned a bachelor's degree in Biology from Emory University and a Ph.D. in Bioengineering from Rice University focused on drug delivery for cancer immunotherapy.



Michelle Stansbury
Vice President, Innovation and IT Applications
Houston Methodist

Michelle Stansbury has been with Houston Methodist since July 1993. Her current position is Vice President of Innovation and Information Technology Applications. During her 29 years at Methodist, she has had many accomplishments. In 2016, Houston Methodist started deployment of Epic to the health and in 2018 established the Center for Innovation.

Houston Methodist received the highest adoption score of Epic functionalities of any new Epic client and the hospitals saw higher operating activity and greater revenue after the deployment of Epic. Her strength is in developing strategy and leading teams to drive those strategic initiatives.

Before joining Houston Methodist, Michelle held leadership roles at Compaq Computer Corporation and Amoco Oil. Her most recent passion is in Digital Health Innovation and has been part of the team leading innovation initiatives at Houston Methodist. Michelle was instrumental in establishment of the Center for Innovation and works closely with Chief Innovation Officer and Chief Information Officer. Within her innovation role, Michelle has responsibilities for day-to-day management of the Innovation Department and has strategic responsibilities for Intelligent Automation and digital transformation of patient access and billing practices. Most recently the innovation center has been focusing on using voice technologies to increase efficiencies and satisfaction for patients, physicians in the outpatient clinic and the Operating Room, and nurses.


Michelle speaks regularly in conferences and panels on innovation, digital transformation and building innovative cultures. She was named as one of the 50 Most Powerful Women in Healthcare IT for 2019 – CIO and IT Executives by Health Data Management Magazine. She was also named as one of the 2020 and 2022 Women to Watch in Health IT by Becker's Hospital Review. In 2021 she was nominated for the HIMSS Changemaker in Health Awards.

Michelle earned her Bachelor degree in Business Administration from Phoenix University. She is a member of the Healthcare Financial Management Association, College of Healthcare Information Management Executives and the Healthcare Information Management and Systems Society.



Ann Tanabe
Texas Life Science Forum Co-Host
Chief Executive Officer
BioHouston

Ann Tanabe, the current Chief Executive Officer of BioHouston, has over 15 years of experience working in numerous roles in the Biotechnology Industry. Ann was promoted to CEO of BioHouston in October 2015 after serving four years as VP of Investor Relations at Synthesis Energy Systems, a publicly traded energy company from May 2008 to December 2010. Preceding her success at both BioHouston and Sythesis Energy Systems, Ann served as VP of Corporate Communications & Investor Relations at Encysive Pharmaceuticals, previously known as Texas Biotechnology.



Brian Toglia
Managing Director/Life Science Practice Leader
Higginbotham

Brian has spent close to a decade focused on the life science industry. He has participated at industry events as a subject matter expert on topics such as cyber liability, supply chain risk management, global clinical trials and 21 CFR Part 11. He currently represents clients across the United States and Europe in all stages of development from start up to clinical stage to commercialization. His consultative approach and experience allow for a unique perspective on a company's operation to identify and address current needs and anticipate future areas of risk. His involvement allows C-suite executives to focus on growing their company while Higginbotham serves as their trusted insurance and risk advisor. Brian graduated cum laude from Pepperdine University in California with a BS in Business Administration and BA in Political Science.



Greg Trujillo
Business Development, Project Executive
DPR Construction

Greg Trujillo is a Business Developer for DPR Construction's Texas region, with 35 years of experience in the construction industry focusing on the Life Science and Pharmaceutical Manufacturing industry. After working in field operations for most of his career performing roles from superintendent to project executive, Greg shifted his talents to business development and customer relationship management for DPR's life science market in Houston. He provides vision, strategic planning and direction, and client coordination with our Austin and Dallas offices.



Jeffrey L. Wade, J.D.
President & Chief Financial Officer
Lexicon Pharmaceuticals

Jeffrey L. Wade is president and CFO of Lexicon Pharmaceuticals, Inc. (Nasdaq: LXR), a biopharmaceutical company with a mission of pioneering transformative new medicines, having previously served in a series of finance, corporate development, administrative and legal executive roles since joining the company in 1999. He has played an instrumental role in completing securities offerings for Lexicon totaling more than \$1 billion; completing the acquisition of Coelacanth Corporation that established the basis for the company's small molecule drug discovery efforts; and negotiating collaborations and licenses involving more than \$1 billion in committed funding to the company, including strategic alliances with Sanofi, Bristol-Myers Squibb, Genentech, Ipsen and Takeda. Before joining Lexicon, Mr. Wade was a partner with the law firm of Andrews & Kurth, where his practice consisted primarily of corporate finance and securities transactions, mergers and acquisitions, and partnerships and alliances. He is a member of the boards of directors of the Texas Healthcare and Bioscience Institute and BioHouston. Mr. Wade received his B.A. (Plan II) and J.D. from The University of Texas.




Dan Watkins, Ph.D.
Venture Partner and Co-Founder of Mercury Fund
CEO of Pelagos Pharma

Dan Watkins is a co-founder and Venture Partner at Mercury, where he focuses on investing in startups that utilize AI and machine learning to drive the next wave of scientific innovation in healthcare, life sciences and industrial markets. Additionally, Dan co-founded Mercury Data Science, an AI/ML strategy and product development studio that provides contract services to fast growing companies. As founder and initial CEO of Courier Therapeutics, Dan helped establish and grow the company resulting in a \$500M exit. He is also a co-founder of the Rice Alliance for Technology and Entrepreneurship at Rice University, with the mission to support the creation and success of startups and the commercialization of new technologies in the Houston community and beyond. Dan received his B.S. from Rice University and his M.S. and Ph.D. from Carnegie Mellon University, all in Materials Science. Outside of Mercury, Dan serves on the advisory boards of Northwestern University's Innovation and New Ventures Office (INVO), the Rice Alliance, and the University of Illinois Proof of Concept Fund Committee.



Megan Wirth
Business Development Manager, Cell & Gene Therapy
Thermo Fisher Scientific

Bio coming soon.



Alicia Yin, Ph.D.
Executive Director
6 Dimensions Capital

Bio coming soon.